-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Downgrades RAPT Therapeutics to Equal-Weight, Announces $58 Price Target

Benzinga·01/21/2026 19:20:44
Listen to the news
Barclays analyst Etzer Darout downgrades RAPT Therapeutics (NASDAQ:RAPT) from Overweight to Equal-Weight and announces $58 price target.